MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

Search

Smith & Nephew PLC ADR

Gesloten

31.87 -5.09

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

31.83

Max

33.58

Belangrijke statistieken

By Trading Economics

Inkomsten

296M

Verkoop

3B

K/W

Sectorgemiddelde

30.342

90.831

Dividendrendement

2.26

Winstmarge

9.895

Werknemers

17,000

EBITDA

723M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+6.15% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.26%

2.20%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

15B

Vorige openingsprijs

36.96

Vorige sluitingsprijs

31.87

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Smith & Nephew PLC ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 jan 2026, 19:05 UTC

Belangrijke Marktbewegers

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

13 jan 2026, 23:41 UTC

Marktinformatie

Nikkei May Rise on Japan Election Hopes -- Market Talk

13 jan 2026, 23:41 UTC

Marktinformatie

Global Equities Roundup: Market Talk

13 jan 2026, 23:33 UTC

Marktinformatie

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

13 jan 2026, 23:13 UTC

Acquisities, Fusies, Overnames

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

13 jan 2026, 23:10 UTC

Acquisities, Fusies, Overnames

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

13 jan 2026, 23:03 UTC

Marktinformatie

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

13 jan 2026, 21:50 UTC

Acquisities, Fusies, Overnames

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

13 jan 2026, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

13 jan 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

13 jan 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

13 jan 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

13 jan 2026, 21:15 UTC

Acquisities, Fusies, Overnames

VERSANT Completes Acquisition Of Free TV Networks >VSNT

13 jan 2026, 21:08 UTC

Acquisities, Fusies, Overnames

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

13 jan 2026, 20:39 UTC

Marktinformatie

Silver Settles at Another New High -- Market Talk

13 jan 2026, 20:21 UTC

Marktinformatie

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

13 jan 2026, 20:17 UTC

Marktinformatie

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

13 jan 2026, 19:08 UTC

Acquisities, Fusies, Overnames

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

13 jan 2026, 19:03 UTC

Winsten

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

13 jan 2026, 18:50 UTC

Winsten

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

13 jan 2026, 17:54 UTC

Marktinformatie

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

13 jan 2026, 17:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

13 jan 2026, 17:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

13 jan 2026, 17:49 UTC

Marktinformatie

Analysts Call For Potential Record Ethanol Output -- Market Talk

13 jan 2026, 17:38 UTC

Marktinformatie

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

13 jan 2026, 17:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

13 jan 2026, 17:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

13 jan 2026, 17:20 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

13 jan 2026, 17:19 UTC

Marktinformatie

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

13 jan 2026, 17:15 UTC

Marktinformatie

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Peer Vergelijking

Prijswijziging

Smith & Nephew PLC ADR Prognose

Koersdoel

By TipRanks

6.15% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 35.75 USD  6.15%

Hoogste 37.5 USD

Laagste 34 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Smith & Nephew PLC ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

2 ratings

0

Buy

2

Hold

0

Sell

Technische score

By Trading Central

26.64 / 28.37Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat